FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent(r) (alirocumab) Injection for Patients with Hypercholesterolemia PARIS and TARRYTOWN, N.Y., June 9, 2015 (GLOBE NEWSWIRE) -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the...

Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis PARIS and TARRYTOWN, N.Y., July 9, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b...

Sanofi and Lilly announce licensing agreement for Cialis(R) (tadalafil) OTC   Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC - Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after...

Sanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus(R) and Lantus(R) SoloStar(R) PARIS, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT:SAN) (NYSE:SNY) announced today that it filed a patent infringement suit against Eli Lilly and Company ( "Lilly") on January 30, 2014 in the...